Paid Clinical Trials Irvine

Discover 3,372 paid clinical trials in Irvine, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 3,372

Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Irvine CA, Orange CA, Anaheim CA, Bellflower CAshow 269 more

Code:

NCT05095376

Conditions

Glioblastoma

Gliosarcoma

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Lomustine

Magnetic Resonance Imaging

Photon Beam Radiation Therapy

Questionnaire Administration

Temozolomide

Mezigdomide & CarfilzomibA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Recruiting

PHASE3

Sponsor:

Bristol-Myers Squibb

Location:

Irvine CA, Cerritos CA, Los Angeles CA, Stockton CAshow 34 more

Code:

NCT05552976

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mezigdomide

Carfilzomib

Dexamethasone

CLN-619 & PembrolizumabA Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting

PHASE1

Sponsor:

Cullinan Therapeutics Inc.

Location:

Irvine CA, Duarte CA, San Antonio TX, Nashville TNshow 8 more

Code:

NCT05117476

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CLN-619

Pembrolizumab

AMT-162Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting

PHASE1

PHASE2

Sponsor:

UniQure Biopharma B.V.

Location:

Irvine CA, San Francisco CA, Fairway KS, Rochester MNshow 6 more

Code:

NCT06100276

Conditions

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AMT-162

CenerimodA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Recruiting

PHASE3

Sponsor:

Idorsia Pharmaceuticals Ltd.

Location:

Riverside CA, Northridge CA, La Jolla CA, Poway CAshow 20 more

Code:

NCT05672576

Conditions

Lupus Erythematosus, Systemic

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Cenerimod

Placebo

LY3541860A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

Recruiting

PHASE2

Sponsor:

Eli Lilly and Company

Location:

Huntington Beach CA, Whittier CA, Covina CA, Tujunga CAshow 16 more

Code:

NCT06859294

Conditions

Rheumatoid Arthritis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

LY3541860

AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Anaheim CA, Long Beach CA, Oceanside CA, San Jose CAshow 35 more

Code:

NCT05711394

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Atogepant

Placebo-Matching Atogepant

LuspaterceptA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Recruiting

PHASE3

Sponsor:

Celgene

Location:

Los Angeles CA, Stanford CA, Oakland CA, Houston TXshow 9 more

Code:

NCT04064060

Conditions

Myelodysplastic Syndromes (MDS)

Beta-thalassemia

Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Luspatercept

Pembrolizumab & ATL-DCPembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recruiting

PHASE1

Sponsor:

Jonsson Comprehensive Cancer Center

Location:

Los Angeles CA

Code:

NCT04201873

Conditions

Recurrent Glioblastoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dendritic Cell Tumor Cell Lysate Vaccine

Pembrolizumab

Placebo Administration

Poly ICLC

Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

PHASE2

Sponsor:

Allogene Therapeutics

Location:

Duarte CA, Los Angeles CA, Gilbert AZ, Berkeley CAshow 33 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide